MG
PRLD icon

Michael Gelband’s Prelude Therapeutics PRLD Stock Holding History

Michael Gelband’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.5K Buy
+15,475
New +$67.4K ﹤0.01% 1470
2024
Q4 		– Sell
-921,621
Closed -$1.91M – 1942
2024
Q3 		$1.91M Buy
+921,621
New +$4.27M 0.01% 755
2022
Q1 		– Sell
-20,773
Closed -$259K – 2579
2021
Q4 		$259K Buy
+20,773
New +$338K ﹤0.01% 1715
2020
Q4 		– Sell
-7,108
Closed -$214K – 2303
2020
Q3 		$214K Buy
+7,108
New +$201K ﹤0.01% 1445

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Michael Gelband's PRLD Position: Q2 2026 in Review

Michael Gelband opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 15,475 shares worth $82.5K. The stake represents ﹤0.01% of the portfolio and ranks #1470 among its holdings. This is a return to the name: Michael Gelband previously reported a position in PRLD as recently as Q3 2024.

Michael Gelband first reported a position in PRLD in Q3 2020 and has held it in 4 quarters since. The position peaked at $1.91M in Q3 2024. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Michael Gelband held 15,475 shares of Prelude Therapeutics worth $82.5K as of Q2 2026.
  • Prelude Therapeutics was a new Michael Gelband position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1470 holding.
  • Michael Gelband first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 4 quarters since.
  • Michael Gelband's Prelude Therapeutics position peaked at $1.91M in Q3 2024.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.